Publications by authors named "Amitkumar N Mehta"

Claim this Profile
N
Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma.
Nathalie A Johnson, Pier Luigi Zinzani, Eva Domingo-Domenech, Joshua Brody, Justin Kline, Amitkumar Nitinkumar Mehta

Future Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma.
Yucai Wang, Melissa C Larson, Steven R Hwang, Diego Villa, Laveniya Kugathasan, Amitkumar Nitinkumar Mehta

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.
Andrew L Coveler, David C Smith, Tycel Phillips, Brendan D Curti, Sanjay Goel, Amitkumar N Mehta

J Immunother Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma.
Neeraj Agarwal, Joaquim Bellmunt, Benjamin L Maughan, Kenneth M Boucher, Toni K Choueiri, Amitkumar N Mehta

Clin Genitourin Cancer· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis